Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety
Ursula A. Matulonis(Dana-Farber Cancer Institute), Robert L. Coleman(Texas Oncology), Bella Kaufman(NYU Langone Health), Tony W. Ho(Johns Hopkins University), Ronnie Shapira‐Frommer(Sheba Medical Center), M. William Audeh(Sheba Medical Center), Karen A. Gelmon(University of British Columbia), S. M. Domchek(QIMR Berghofer Medical Research Institute), Helen Mann(AstraZeneca (United Kingdom)), Richard T. Penson(Massachusetts General Hospital), S.B. Kaye(Western Infirmary), Jane Robertson(Cancer Research UK), L. Rhoda Molife(Royal Marsden NHS Foundation Trust)
Cited by 159
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k